Supplementary table 1. Table of Clinical outcomes post pancreatitis by Quintile

	Q1	Q2	Q3	Q4	Q5	P-value
Superior	12	7 (7.45%)	4 (6.67%)	5 (10.4%)	4 (10.5%)	0.790
mesenteric vein	(7.69%)					
thrombus (yes)						
Revised Atlanta cl	assification c	of acute pand	creatitis			
Severe	41	29	27 (45%)	11	13	0.939
	(26.3%)	(30.9%)		(22.9%)	(34.2%)	
Mod	95	48	19	33	18	
	(60.9%)	(51.1%)	(31.7%)	(68.8%)	(47.4%)	
Mild	20	17	14	4 (8.33%)	7 (18.4%)	
	(12.8%)	(18.1%)	(23.3%)			
Organ failure						
None	109	63	30 (50%)	35	24	0.351
	(69.9%)	(67.0%)		(72.9%)	(63.2%)	
Persistent	36	26	29	12 (25%)	13	
	(23.1%)	(27.7%)	(48.3%)		(34.2%)	
Transient	11	5 (5.32%)	1 (1.67%)	1 (2.08%)	1 (2.63%)	
	(7.05%)					
Splenic vein	31	17	5 (8.33%)	10	10	0.789
thrombus (SVT)	(19.9%)	(18.1%)		(20.8%)	(26.3%)	
Portal vein	23	13	9 (15%)	8 (16.7%)	9 (23.7%)	0.687
thrombus (PVT)	(14.7%)	(13.8%)				
Combined PVT	12	5 (5.32%)	1 (1.67%)	4 (8.33%)	5 (13.2%)	0.232
and SVT	(7.69%)					
Pancreas	98	53	35	35	24	0.397
necrosis	(62.8%)	(56.4%)	(58.3%)	(72.9%)	(63.2%)	
Pseudoaneurysm	3 (1.92%)	0 (0%)	2 (3.33%)	3 (6.25%)	0 (0%)	0.110
Total intensive car	e unit visits					
0	118	67	34	36 (75%)	25	0.208
	(75.6%)	(71.3%)	(56.7%)		(65.8%)	
1	29	22	22	10	12	
	(18.6%)	(23.4%)	(36.7%)	(20.8%)	(31.6%)	
2	3 (1.92%)	2 (2.13%)	1 (1.67%)	2 (4.17%)	1 (2.63%)	
3	3 (1.92%)	2 (2.13%)	2 (3.33%)	0 (0%)	0 (0%)	
Number of organs	supported	1	T	_	1	,
0	118	71	35	38	26	0.114
	(75.6%)	(75.5%)	(58.3%)	(79.2%)	(68.4%)	
1	19	13	15 (25%)	3 (6.25%)	9 (23.7%)	
	(12.2%)	(13.8%)				
2	10	9 (9.57%)	8 (13.3%)	7 (14.6%)	3 (7.89%)	
	(6.41%)					
Pancreatic enzyme	e replacemei	nt therapy				
Yes	98	58	33 (55%)	29	23	0.717
	(62.8%)	(61.7%)		(60.4%)	(60.5%)	
Intensive care uni	ts stay					

Mean (S.D)	4 (14)	6 (16)	14 (32	9 (27)	5(14)	0.035*			
Median (IQR)	0(0-0)	0(0-8)	0(0-13)	0(0-0)	0(0-3)				
Overall Stay									
Mean (S.D)	31(28)	32(37)	42(45)	36(50)	28(23)	0.271			
Median (IQR)	20(13-39)	20 (13- 37)	26(14-40)	17(11-33)	22(13-36)				

^{*}Statistically significant at <0.05 level